Skip to main content
SpringerLink
Log in

Systemic Treatment of Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck

  • Chapter
  • First Online:
Head and Neck Cancer

Abstract

Most patients with recurrent or metastatic head and neck squamous cell cancers qualify for palliative treatment. The management of these patients includes supportive care only, mono- or multiagent chemotherapy, and more recently targeted therapies. While platinum-based combinations are superior to single-agent therapies in terms of response rate, they are more toxic and so far have not shown to lead to meaningful survival benefit. Attempts to improve on this by using other or additional cytotoxic drugs were unsuccessful in the last 30 years. It was therefore an urgent need to investigate the efficacy of novel anticancer therapies that specifically target the tumor cells in such patients. A recent randomized trial showed that adding cetuximab, an EGFR-directed monoclonal antibody, to a standard platinum-based chemotherapy regimen led to an important survival benefit. Despite the still dismal prognosis, the outcome of this latter trial has changed practice in this category of head and neck cancer patients. The next challenge will be to sort out how to incorporate the numerous targeted agents that are currently studied into the existing treatment strategies, also in consideration of an optimization of their therapeutic index. Human papillomavirus status with immunohistochemical p16 expression as its surrogate marker represents promising prognostic and possibly predictive biomarkers that need to be prospectively validated in future randomized trials.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 219.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 279.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 279.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Licitra L, Locati LD, Bossi P. Optimizing approaches to head and neck cancer. Metastatic head and neck cancer: new options. Ann Oncol. 2008;19:vii200–3.

    Article  PubMed  Google Scholar 

  2. Vermorken JB. Medical treatment in head and neck cancer. Ann Oncol. 2005;16:ii258–64.

    PubMed  Google Scholar 

  3. Colevas AD. Chemotherapy options for patients with metastatic or recurrent squamous cell carcinoma of the head and neck. J Clin Oncol. 2006;24:2644–52.

    Article  CAS  PubMed  Google Scholar 

  4. Al-Sarraf M. Head and neck cancer: chemotherapy concepts. Semin Oncol. 1988;15:70–85.

    CAS  PubMed  Google Scholar 

  5. Amer MH, Al-Sarraf M, Vaitkevicius VK. Factors that affect response to chemotherapy and survival of patients with advanced head and neck cancer. Cancer. 1979;42:2202–6.

    Article  Google Scholar 

  6. Forastiere AA, Metch B, Schuller DE, et al. Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous-cell carcinoma of the head and neck: a Southwest Oncology Group study. J Clin Oncol. 1992;10:1245–51.

    CAS  PubMed  Google Scholar 

  7. Jacobs C, Lyman G, Velez-García E, et al. A phase III randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck. J Clin Oncol. 1992;10:257–63.

    CAS  PubMed  Google Scholar 

  8. Stell PM, McCormick MS. The design of phase III palliative chemotherapy trials in head and neck cancer. Clin Otolaryngol Allied Sci. 1986;11:21–9.

    Article  CAS  PubMed  Google Scholar 

  9. Argiris A, Li Y, Forastiere A. Prognostic factors and long/term survivorship in patients with recurrent or metastatic carcinoma of the head and neck. An analysis of two Eastern Cooperative Oncology Group randomized trials. Cancer. 2004;101:2222–9.

    Article  PubMed  Google Scholar 

  10. León X, Hitt R, Constenla M, et al. A retrospective analysis of the outcome of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck refractory to a platinum-based chemotherapy. Clin Oncol. 2005;17:418–24.

    Article  Google Scholar 

  11. Pivot X, Wadler S, Kelly C, et al. Result of two randomized trials comparing nolatrexed (Thymitaq) versus methotrexate in patients with recurrent head and neck cancer. Ann Oncol. 2001;12:1595–9.

    Article  CAS  PubMed  Google Scholar 

  12. Stewart JS, Cohen EE, Licitra L, et al. Phase III study of gefitinib compared with intravenous methotrexate for recurrent squamous cell carcinoma of the head and neck. J Clin Oncol. 2009;27:1864–71.

    Article  CAS  PubMed  Google Scholar 

  13. Machiels JP, Subramanian S, Ruzsa A, et al. Zalutumumab plus best supportive care versus best supportive care alone in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck after failure of platinum-based chemotherapy: an open-label, randomised phase 3 trial. Lancet Oncol. 2011;12:333–43.

    Article  CAS  PubMed  Google Scholar 

  14. Numico G, Merlano M. Second-line treatment with docetaxel after failure of a platinum-based chemotherapy in squamous-cell head and neck cancer. Ann Oncol. 2002;13:331–3.

    Article  CAS  PubMed  Google Scholar 

  15. Zenda S, Onozawa Y, Boku N, Iida Y, Ebihara M, Onitsuka T. Single-agent docetaxel in patients with platinum-refractory metastatic or recurrent squamous cell carcinoma of the head and neck (SCCHN). Jpn J Clin Oncol. 2007;37:477–81.

    Article  PubMed  Google Scholar 

  16. Specenier P, Rasschaert M, Vroman P, et al. Weekly docetaxel in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. Am J Clin Oncol. 2011;34:472–7.

    Article  CAS  PubMed  Google Scholar 

  17. Argiris A, Ghebremichael M, Gilbert J, et al. Phase III randomized, placebo-controlled trial of docetaxel with or without gefitinib in recurrent or metastatic head and neck cancer: an eastern cooperative oncology group trial. J Clin Oncol. 2013;31:1405–14.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Urba SG, Forastiere AA. Systemic therapy of head and neck cancer: most effective agents, areas of promise. Oncology (Williston Park). 1989;4:79–88.

    Google Scholar 

  19. Kish JA, Ensley JF, Jacobs J, Weaver A, Cummings G, Al-Sarraf M. A randomized trial of cisplatin (CACP) and 5-fluorouracil (5-FU) infusion and CACP + 5-FU bolus for recurrent and advanced squamous cell carcinoma of the head and neck. Cancer. 1985;56:2740–4.

    Article  CAS  PubMed  Google Scholar 

  20. Amrein PC, Weitzman SA. Treatment of squamous cell carcinoma of the head and neck with cisplatin and 5-fluorouracil. J Clin Oncol. 1985;3:1632–9.

    CAS  PubMed  Google Scholar 

  21. Tannock IF. Chemotherapy for head and neck cancer. J Otolaryngol. 1984;13:99–104.

    CAS  PubMed  Google Scholar 

  22. Al-Sarraf M. Chemotherapy strategies in squamous cell carcinoma of the head and neck. Crit Rev Oncol Hematol. 1984;1:323–55.

    Article  CAS  PubMed  Google Scholar 

  23. Carter SK, Slavik M. Current investigational drugs of interest in the chemotherapy program of the National Cancer Institute. Natl Cancer Inst Monogr. 1977;45:101–21.

    PubMed  Google Scholar 

  24. Clavel M, Vermorken JB, Cognetti F, et al. Randomized comparison of cisplatin, methotrexate, bleomycin and vincristine (CABO) versus cisplatin and 5-fluorouracil (CF) versus cisplatin (C) in recurrent or metastatic squamous cell carcinoma of the head and neck. A phase III study of the EORTC Head and Neck Cancer Cooperative Group. Ann Oncol. 1994;5:521–6.

    CAS  PubMed  Google Scholar 

  25. Hong WK, Schaefer S, Issell B, et al. A prospective randomized trial of methotrexate versus cisplatin in the treatment of recurrent squamous cell carcinoma of the head and neck. Cancer. 1983;52:206–10.

    Article  CAS  PubMed  Google Scholar 

  26. Eisenberger M, Hornedo J, Silva H, et al. Carboplatin (NSC-241-240): an active platinum analog for the treatment of squamous-cell carcinoma of the head and neck. J Clin Oncol. 1986;4:1506–9.

    CAS  PubMed  Google Scholar 

  27. Wittes RE. Chemotherapy of head and neck cancer. Otolaryngol Clin North Am. 1980;13:515–20.

    CAS  PubMed  Google Scholar 

  28. Glick JH, Zehngebot LM, Taylor SG. Chemotherapy for squamous cell carcinoma of the head and neck: a progress report. Am J Otolaryngol. 1980;1:306–23.

    Article  CAS  PubMed  Google Scholar 

  29. Airoldi M, Cortesina G, Giordano C, et al. Ifosfamide in the treatment of head and neck cancer. Oncology. 2003;65(Suppl2):37–43.

    Article  CAS  PubMed  Google Scholar 

  30. Schrijvers D, Vermorken JB. Taxanes in head and neck cancer. Future Oncol. 2005;1:829–39.

    Article  CAS  PubMed  Google Scholar 

  31. Grau JJ, Caballero M, Verger E, Monzo M, Blanch JL. Weekly paclitaxel for platin-resistant stage IV head and neck cancer patients. Acta Otolaryngol. 2009;129:1294–9.

    Article  CAS  PubMed  Google Scholar 

  32. Pivot X, Raymond E, Laguerre B, et al. Pemetrexed disodium in recurrent locally advanced or metastatic squamous cell carcinoma of the head and neck. Br J Cancer. 2001;85:649–55.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Testolin A, Recher G, Cristoferi V, et al. Vinorelbine in pre-treated advanced head and neck squamous cell carcinoma: a phase II study. Invest New Drugs. 1994;12:213–34.

    Article  Google Scholar 

  34. Degardin M, Oliveira J, Geoffrois L, et al. An EORTC-ECSG phase II study of vinorelbine in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. Ann Oncol. 1998;9:1103–7.

    Article  CAS  PubMed  Google Scholar 

  35. Martinez-Trufero J, Isla D, Adansa JC, et al. Phase II study of capecitabine as palliative treatment for patients with recurrent and metastatic squamous head and neck cancer after previous platinum-based treatment. Br J Cancer. 2010;102:1687–91.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. Murphy BA. Topoisomerases in the treatment of metastatic or recurrent squamous carcinoma of the head and neck. Expert Opin Pharmacother. 2005;6:85–92.

    Article  CAS  PubMed  Google Scholar 

  37. Kuebler JP, Benedetti J, Schuller DE, et al. Phase II study of edatrexate in advanced head and neck cancer. A Southwest Oncology Group study. Invest New Drugs. 1994;12:341–4.

    Article  CAS  PubMed  Google Scholar 

  38. Schornagel JH, Verweij J, de Mulder PH, et al. Randomized phase III trial of edatrexate versus methotrexate in patients with metastatic and/or recurrent squamous cell carcinoma of the head and neck: a European Organization for Research and Treatment of Cancer Head and Neck Cancer Cooperative Group study. J Clin Oncol. 1995;13:1649–55.

    CAS  PubMed  Google Scholar 

  39. Park S, Lee S, Park J, Cho E, Shin D, Lee J. Phase II study of oral S-1 in pretreated patients with recurrent or metastatic head and neck cancer. J Clin Oncol. 2008;26:692s. Abstract 17007.

    Article  Google Scholar 

  40. Hitt R, Amador ML, Quintela-Fandino M, et al. Weekly docetaxel in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. Cancer. 2006;106:106–11.

    Article  CAS  PubMed  Google Scholar 

  41. Colevas AD, Amrein PC, Gomolin H, et al. A phase II study of combined oral uracil and ftorafur with leucovorin for patients with squamous cell carcinoma of the head and neck. Cancer. 2001;92:326–31.

    Article  CAS  PubMed  Google Scholar 

  42. Grose WE, Lehane DE, Dixon DO, Fletcher WS, Stuckey WJ. Comparison of methotrexate and cisplatin for patients with advanced squamous cell carcinoma of the head and neck region: a Southwest Oncology Group study. Cancer Treat Rep. 1985;69:577–81.

    CAS  PubMed  Google Scholar 

  43. Vermorken JB, Catimel G, de Mulder P, et al. Randomized phase II trial of weekly methotrexate versus two schedules of three-weekly paclitaxel in patients with metastatic or recurrent squamous cell carcinoma of the head and neck. Proc Am Soc Clin Oncol. 1999;18:395a. Abstract 1527.

    Google Scholar 

  44. Guardiola E, Peyrade F, Chaigneau L, et al. Results of a randomised phase II study comparing docetaxel with methotrexate in patients with recurrent head and neck cancer. Eur J Cancer. 2004;40:2071–6.

    Article  CAS  PubMed  Google Scholar 

  45. Morton RP, Rugman F, Dorman EB, et al. Cisplatinum and bleomycin for advanced or recurrent squamous cell carcinoma of the head and neck: a randomised factorial phase III controlled trial. Cancer Chemother Pharmacol. 1985;15:283–9.

    Article  CAS  PubMed  Google Scholar 

  46. De Andres L, Brunet J, Lopez-Pousa A, et al. Randomized trial of neoadjuvant cisplatin and fluorouracil versus carboplatin and fluorouracil in patients with stage IV-M0 head and neck cancer. J Clin Oncol. 1995;13:1493–500.

    PubMed  Google Scholar 

  47. Eisenberger M, Krasnow S, Ellenberg S, et al. A comparison of carboplatin plus methotrexate versus methotrexate alone in patients with recurrent and metastatic head and neck cancer. J Clin Oncol. 1989;7:1341–5.

    CAS  PubMed  Google Scholar 

  48. Clavel M, Cognetti F, Dodion P, et al. Combination chemotherapy with methotrexate, bleomycin, and vincristine with or without cisplatin in advanced squamous cell carcinoma of the head and neck. Cancer. 1987;60:1173–7.

    Article  CAS  PubMed  Google Scholar 

  49. Urba S, van Herpen CM, Sahoo TP, et al. Pemetrexed in combination with cisplatin versus cisplatin monotherapy in patients with recurrent or metastatic head and neck cancer: final results of a randomized, double-blind, placebo-controlled, phase 3 study. Cancer. 2012;118:4694–705.

    Article  CAS  PubMed  Google Scholar 

  50. Schantz SP, Harrison LB, Forastiere AA. Tumors of the nasal cavity and paranasal sinuses, nasopharynx, oral cavity, and oropharynx. In: DeVita VT, Hellman S, Rosenberg SA, editors. Cancer: principles & practice of oncology. 6th ed. Philadelphia: Lippincott-Raven; 2001. p. 797–860.

    Google Scholar 

  51. Shin DM, Glisson BS, Khuri FR, et al. Phase II trial of paclitaxel, ifosfamide, and cisplatin in patients with recurrent head and neck squamous cell carcinoma. J Clin Oncol. 1998;16:1325–30.

    CAS  PubMed  Google Scholar 

  52. Shin DM, Khuri FR, Glisson BS, et al. Phase II study of paclitaxel, ifosfamide, and carboplatin in patients with recurrent or metastatic head and neck squamous cell carcinoma. Cancer. 2001;91:1316–23.

    Article  CAS  PubMed  Google Scholar 

  53. Samlowski WE, Moon J, Kuebler JP, et al. Evaluation of the combination of docetaxel/carboplatin in patients with metastatic or recurrent squamous cell carcinoma of the head and neck (SCCHN): a Southwest Oncology Group phase II study. Cancer Invest. 2007;25:182–8.

    Article  CAS  PubMed  Google Scholar 

  54. Gibson MK, Li Y, Murphy B, et al. Randomized phase III evaluation of cisplatin plus fluorouracil versus cisplatin plus paclitaxel in advanced head and neck cancer (E1395): an Intergroup trial of the Eastern Cooperative Oncology Group. J Clin Oncol. 2005;23:3562–7.

    Article  CAS  PubMed  Google Scholar 

  55. Janinis J, Papadakou M, Xidakis E, et al. Combination chemotherapy with docetaxel, cisplatin, and 5-fluorouracil in previously treated patients with advanced/recurrent head and neck cancer: a phase II feasibility study. Am J Clin Oncol. 2000;23:128–31.

    Article  CAS  PubMed  Google Scholar 

  56. Benasso M, Ponzanelli A, Merlano M, et al. Paclitaxel, cisplatin and 5-fluorouracil in recurrent squamous cell carcinoma of the head and neck: a phase II trial from an Italian cooperative group. Acta Oncol. 2006;45:168–74.

    Article  CAS  PubMed  Google Scholar 

  57. Specenier P, Vermorken JB. Targeted therapies in head and neck cancer. Targeted Oncol. 2007;2:73–8.

    Article  Google Scholar 

  58. Ugurluer G, Ozsahin M. Early investigational drugs that target epidermal growth factor receptors for the treatment of head and neck cancer. Expert Opin Investig Drugs. 2014;23:1637–54.

    Article  CAS  PubMed  Google Scholar 

  59. Schmitz S, Ang KK, Vermorken J, et al. Targeted therapies for squamous cell carcinoma of the head and neck: current knowledge and future directions. Cancer Treat Rev. 2014;40:390–404.

    Article  CAS  PubMed  Google Scholar 

  60. Zandberg DP, Strome SE. The role of the PD-L1:PD-1 pathway in squamous cell carcinoma of the head and neck. Oral Oncol. 2014;50:627–32.

    Article  CAS  PubMed  Google Scholar 

  61. Xia W, Lau YK, Zhang HZ, et al. Combination of EGFR, HER-2/neu, and HER-3 is a stronger predictor for the outcome of oral squamous cell carcinoma than any individual family members. Clin Cancer Res. 1999;5:4164–74.

    CAS  PubMed  Google Scholar 

  62. Ang KK, Berkey BA, Tu X, et al. Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma. Cancer Res. 2002;62:7350–6.

    CAS  PubMed  Google Scholar 

  63. Chung CH, Ely K, McGavran L, et al. Increased epidermal growth factor receptor gene copy number is associated with poor prognosis in head and neck squamous cell carcinomas. J Clin Oncol. 2006;24:4170–6.

    Article  CAS  PubMed  Google Scholar 

  64. Eriksen JG, Steiniche T, Askaa J, et al. The prognostic value of epidermal growth factor receptor is related to tumor differentiation and the overall treatment time of radiotherapy in squamous cell carcinomas of the head and neck. Int J Radiat Oncol Biol Phys. 2004;58:561–6.

    Article  CAS  PubMed  Google Scholar 

  65. Santini J, Formento JL, Francoual M, et al. Characterization, quantification, and potential clinical value of the epidermal growth factor receptor in head and neck squamous cell carcinomas. Head Neck. 1991;13:132–9.

    Article  CAS  PubMed  Google Scholar 

  66. Licitra L, Störkel S, Kerr KM, et al. Predictive value of epidermal growth factor receptor expression for first-line chemotherapy plus cetuximab in patients with head and neck and colorectal cancer: analysis of data from the EXTREME and CRYSTAL studies. Eur J Cancer. 2013;49:1161–8.

    Article  CAS  PubMed  Google Scholar 

  67. Licitra L, Mesia R, Rivera F, et al. Evaluation of EGFR gene copy number as a predictive biomarker for the efficacy of cetuximab in combination with chemotherapy in the first-line treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck: EXTREME study. Ann Oncol. 2011;22:1078–87.

    Article  CAS  PubMed  Google Scholar 

  68. Scaltriti M, Baselga J. The epidermal growth receptor pathway: a model for targeted therapy. Clin Cancer Res. 2006;12:5268–72.

    Article  CAS  PubMed  Google Scholar 

  69. Kimura H, Sakai K, Arao T, Shimoyama T, Tamura T, Nishio K. Antibody-dependent cellular cytotoxicity of cetuximab against tumor cells with wild-type or mutant epidermal growth factor receptor. Cancer Sci. 2007;98:1275–80.

    Article  CAS  PubMed  Google Scholar 

  70. Bleeker WK, Lammerts van Bueren JJ, van Ojik HH, et al. Dual mode of action of a human anti-epidermal growth factor receptor monoclonal antibody for cancer therapy. J Immunol. 2004;173:4699–707.

    Article  CAS  PubMed  Google Scholar 

  71. Schneider-Merck T, Lammerts van Bueren JJ, Berger S, et al. Human IgG2 antibodies against epidermal growth factor receptor effectively trigger antibody-dependent cellular cytotoxicity but, in contrast to IgG1, only by cells of myeloid lineage. J Immunol. 2010;184:512–20.

    Article  CAS  PubMed  Google Scholar 

  72. Rapidis AD, Vermorken JB, Bourhis J. Targeted therapies in head and neck cancer: past, present and future. Rev Recent Clin Trials. 2008;3:156–66.

    Article  CAS  PubMed  Google Scholar 

  73. Huang S, Armstrong EA, Benavente S, Chinnaiyan P, Harari PM. Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor. Cancer Res. 2004;64:5355–62.

    Article  CAS  PubMed  Google Scholar 

  74. Matar P, Rojo F, Cassia R, et al. Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting. Clin Cancer Res. 2004;10:6487–501.

    Article  CAS  PubMed  Google Scholar 

  75. Baselga J, Trigo JM, Bourhis J, et al. Phase II multicenter study of the antiepidermal growth factor receptor monoclonal antibody cetuximab in combination with platinum-based chemotherapy in patients with platinum-refractory metastatic and/or recurrent squamous cell carcinoma of the head and neck. J Clin Oncol. 2005;23:5568–77.

    Article  CAS  PubMed  Google Scholar 

  76. Herbst RS, Arquette M, Shin DM, et al. Phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck. J Clin Oncol. 2005;23:5578–87.

    Article  CAS  PubMed  Google Scholar 

  77. Vermorken JB, Trigo J, Hitt R, et al. Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy. J Clin Oncol. 2007;25:2171–7.

    Article  CAS  PubMed  Google Scholar 

  78. Bourhis J, Rivera F, Mesia R, et al. Phase I/II study of cetuximab in combination with cisplatin or carboplatin and fluorouracil in patients with recurrent or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol. 2006;24:2866–72.

    Article  CAS  PubMed  Google Scholar 

  79. Hitt R, Irigoyen A, Cortes-Funes H, et al. Phase II study of the combination of cetuximab and weekly paclitaxel in the first-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of head and neck. Ann Oncol. 2012;23:1016–22.

    Article  CAS  PubMed  Google Scholar 

  80. Buentzel J, de Vries A, Micke O. Experience with cetuximab plus paclitaxel/carboplatinum in primary platinum-resistant recurrent head and neck cancer. J Clin Oncol. 2007;25:318s. Abstract 6077.

    Google Scholar 

  81. Burtness B, Goldwasser MA, Flood W, Mattar B, Forastiere AA, Eastern Cooperative Oncology Group. Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study. J Clin Oncol. 2005;23:8646–54.

    Article  PubMed  Google Scholar 

  82. Vermorken JB, Mesia R, Rivera F, et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med. 2008;359:1116–27.

    Article  CAS  PubMed  Google Scholar 

  83. Vermorken JB, Remenar E, Hitt R, et al. Platinum-based chemotherapy (CT) plus cetuximab in recurrent or metastatic squamous cell carcinoma of the head and neck cancer (R/M-SCCHN): 5-year follow-up data for the extreme trial. J Clin Oncol. 2014;32:5s. Abstract 6021.

    Article  CAS  Google Scholar 

  84. Petrelli NJ, Winer EP, Brahmer J, et al. Clinical cancer advances 2009 major research advances in cancer treatment, prevention, and screening—a report from the American Society of Clinical Oncology. J Clin Oncol. 2009;27:6052–69.

    Article  PubMed  Google Scholar 

  85. Guigay J, Fayette J, Dillies AF, et al. Cetuximab, docetaxel, and cisplatin (TPEx) as first-line treatment in patients with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): final results of phase II trial GORTEC 2008-03. J Clin Oncol. 2012;30:15s. Abstract 5505.

    Article  Google Scholar 

  86. Vermorken JB, Licitra L, Stöhlmacher-Williams J, et al. Phase II study of pemetrexed in combination with cisplatin and cetuximab in recurrent or metastatic squamous cell carcinoma of the head and neck. Eur J Cancer. 2013;49:2877–83.

    Article  CAS  PubMed  Google Scholar 

  87. Carteni G, Fiorentino R, Vecchione L, Chiurazzi B, Battista C. Panitumumab a novel drug in cancer treatment. Ann Oncol. 2007;18:vi16–21.

    Article  PubMed  Google Scholar 

  88. Rishchin D, Spigel D, Adkins D, et al. PRISM: primary efficacy results of a phase 2 trial with panitumumab monotherapy as second-line treatment with recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN). In: Multidisciplinary head and neck symposium; 2011. Abstract 169.

    Google Scholar 

  89. Wirth LJ, Dakhil SR, Kornek G, et al. PARTNER: a randomized phase II study of docetaxel/cisplatin (doc/cis) chemotherapy with or without panitumumab (pmab) as first-line treatment (tx) for recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN). J Clin Oncol. 2013;31. Abstract 6029.

    Google Scholar 

  90. Vermorken JB, Stöhlmacher-Williams J, Davidenko I, et al. Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial. Lancet Oncol. 2013;14:697–710.

    Article  CAS  PubMed  Google Scholar 

  91. Bier H, Hoffman T, Hauser U, et al. Clinical trial with escalating doses of the antiepidermal growth factor receptor humanized monoclonal antibody EMD72000 in patients with advanced squamous cell carcinoma of the larynx and hypopharynx. Cancer Chemother Pharmacol. 2001;47:519–24.

    Article  CAS  PubMed  Google Scholar 

  92. Arteaga ME, Ledón N, Casacó A, et al. Systemic and skin toxicity in Cercopithecus aethiops sabaeus monkeys treated during 26 weeks with a high intravenous dose of the anti-epidermal growth factor receptor monoclonal antibody nimotuzumab. Cancer Biol Ther. 2007;6:1390–5.

    Article  CAS  PubMed  Google Scholar 

  93. Ramakrishnan MS, Eswaraiah A, Crombet T, et al. Nimotuzumab, a promising therapeutic monoclonal for treatment of tumors of epithelial origin. mAbs. 2009;1:41–8.

    Article  PubMed  PubMed Central  Google Scholar 

  94. Soulieres D, Senzer NN, Vokes EE, Hidalgo M, Agarwala SS, Siu LL. Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck. J Clin Oncol. 2004;22:77–85.

    Article  CAS  PubMed  Google Scholar 

  95. Cohen EE, Rosen F, Stadler WM, et al. Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol. 2003;21:1980–7.

    Article  CAS  PubMed  Google Scholar 

  96. Cohen EE, Kane MA, List MA, et al. Phase II trial of gefitinib 250 mg daily in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. Clin Cancer Res. 2005;11:8418–24.

    Article  CAS  PubMed  Google Scholar 

  97. Kirby AM, A’Hern RP, D’Ambrosio C, et al. Gefitinib (ZD1839, Iressa) as palliative treatment in recurrent or metastatic head and neck cancer. Br J Cancer. 2006;94:631–6.

    CAS  PubMed  PubMed Central  Google Scholar 

  98. De Souza JA, Davis DW, Zhang Y, et al. A phase II study of lapatinib in recurrent/metastatic squamous cell carcinoma of the head and neck. Clin Cancer Res. 2012;18:2336–43.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  99. Cohen EE, Halpern AB, Kasza K, et al. Factors associated with clinical benefit from epidermal growth factor receptor inhibitors in recurrent and metastatic squamous cell carcinoma of the head and neck. Oral Oncol. 2009;45:155–60.

    Article  CAS  Google Scholar 

  100. Seiwert TY, Fayette J, Cupissol D, et al. A randomized, phase II study of afatinib versus cetuximab in metastatic or recurrent squamous cell carcinoma of the head and neck. Ann Oncol. 2014;25:1813–20.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  101. Abdul Razak AR, Soulières D, Laurie SA, et al. A phase II trial of dacomitinib, an oral pan-human EGF receptor (HER) inhibitor, as first-line treatment in recurrent and/or metastatic squamous-cell carcinoma of the head and neck. Ann Oncol. 2013;24:761–9.

    Article  CAS  PubMed  Google Scholar 

  102. Machiels JP, Haddad RI, Fayette J, et al. Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): an open-label, randomised phase 3 trial. Lancet Oncol. 2015;16:583–94.

    Article  CAS  PubMed  Google Scholar 

  103. Siu LL, Soulieres D, Chen EX, et al. Phase I/II trial of erlotinib and cisplatin in patients with recurrent or metastatic squamous cell carcinoma of the head and neck: a Princess Margaret Hospital phase II consortium and National Cancer Institute of Canada Clinical Trials Group study. J Clin Oncol. 2007;25:2178–83.

    Article  CAS  PubMed  Google Scholar 

  104. Belon J, Irigoyen A, Rodriguez I, et al. Preliminary results of a phase II study to evaluate gefitinib combined with docetaxel and cisplatin in patients with recurrent and/or metastatic squamous-cell carcinoma of the head and neck. J Clin Oncol. 2005;23:515s. Abstract 5563.

    Google Scholar 

  105. Kim ES, Kies MS, Glisson BS, et al. Final results of a phase II study of erlotinib, docetaxel and cisplatin in patients with recurrent/metastatic head and neck cancer. J Clin Oncol. 2007;25:302s. Abstract 5521.

    Google Scholar 

  106. Weiss J, Hayes DN, Algazy K, et al. Combination lapatinib and capecitabine in advanced, incurable squamous cell carcinoma of the head and neck (SCCHN). J Clin Oncol. 2013;31. Abstract 6094.

    Google Scholar 

  107. Boeckx C, Baay M, Wouters A, et al. Anti-epidermal growth factor receptor therapy in head and neck squamous cell carcinoma: focus on potential molecular mechanisms of drug resistance. Oncologist. 2013;18:850–64.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  108. Fayette J, Wirth L, Oprean C, Hitt R, Udrea A, Jimeno A, et al. Randomized phase II study of MEHD7945A (MEHD) vs cetuximab (Cet) in >= 2nd-line recurrent/metastatic squamous cell Carcinoma of the head & neck (RMSCCHN) progressive on/after platinum-based chemotherapy (PtCT). Ann Oncol. 2014;25:iv340–56. Abstract 986O.

    Google Scholar 

  109. Vermorken JB. Molecular targeted drugs for head and neck cancer. Ann Oncol. 2013;24:ix21. Abstract SY4–1.

    Article  Google Scholar 

  110. Kyzas PA, Stefanou D, Batistatou A, Agnantis NJ. Prognostic significance of VEGF immunohistochemical expression and tumor angiogenesis in head and neck squamous cell carcinoma. J Cancer Res Clin Oncol. 2005;131:624–30.

    Article  CAS  PubMed  Google Scholar 

  111. Kyzas PA, Cunha IW, Ioannidis JP. Prognostic significance of vascular endothelial growth factor immunohistochemical expression in head and neck squamous cell carcinoma: a meta-analysis. Clin Cancer Res. 2005;11:1434–40.

    Article  CAS  PubMed  Google Scholar 

  112. Seiwert TY, Haraf DJ, Cohen EEW, et al. Phase I study of bevacizumab added to fluorouracil- and hydroxyurea-based concomitant chemoradiotherapy for poor-prognosis head and neck cancer. J Clin Oncol. 2008;26:1732–41.

    Article  CAS  PubMed  Google Scholar 

  113. Argiris A, Karamouzis MV, Gooding WE, et al. Phase II trial of pemetrexed and bevacizumab in patients with recurrent or metastatic head and neck cancer. J Clin Oncol. 2011;29:1140–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  114. Machiels JP, Henry S, Zanetta S, et al. Phase II study of sunitinib in recurrent or metastatic squamous cell carcinoma of the head and neck: GORTEC 2006-01. J Clin Oncol. 2010;28:21–8.

    Article  CAS  PubMed  Google Scholar 

  115. Blumenschein GR, Glisson BS, Lu C, et al. Final results of a phase II study of sorafenib in combination with carboplatin and paclitaxel in patients with metastatic or recurrent squamous cell cancer of the head and neck (SCCHN). J Clin Oncol. 2012;30:15s. Abstract 5592.

    Article  CAS  Google Scholar 

  116. Vermorken JB, Peyrade F, Krauss J, et al. Cisplatin, 5-fluorouracil, and cetuximab (PFE) with or without cilengitide in recurrent/metastatic squamous cell carcinoma of the head and neck: results of the randomized phase I/II ADVANTAGE trial (phase II part). Ann Oncol. 2014;25:682–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  117. Cohen EE, Davis DW, Karrison TG, et al. Erlotinib and bevacizumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck: a phase I/II study. Lancet Oncol. 2009;10:247–57.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  118. Argiris A, Kotsakis AP, Hoang T, et al. Cetuximab and bevacizumab: preclinical data and phase II trial in recurrent or metastatic squamous cell carcinoma of the head and neck. Ann Oncol. 2013;24:220–5.

    Article  CAS  PubMed  Google Scholar 

  119. Gildener-Leapman N, Ferris RL, Bauman JE. Promising systemic immunotherapies in head and neck squamous cell carcinoma. Oral Oncol. 2013;49:1089–96.

    Article  PubMed  PubMed Central  Google Scholar 

  120. Wallis SP, Stafford ND, Greenman J. The clinical relevance of immune parameters in the tumor microenvironment of head and neck cancers. Head Neck. 2015;37:449–59.

    Article  PubMed  Google Scholar 

  121. Naidoo J, Page DB, Wolchok JD. Immune modulation for cancer therapy. Br J Cancer. 2014;111:2214–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  122. Saloura V, Zuo Z, Koeppen H, et al. Correlation of T-cell inflamed phenotype with mesenchymal subtype, expression of PD-L1, and other immune checkpoints in head and neck cancer. J Clin Oncol. 2014;32:5s. Abstract 6009.

    Article  CAS  Google Scholar 

  123. Seiwert TY, Burtness B, Weiss J, et al. A phase Ib study of MK-3475 in patients with human papillomavirus (HPV)-associated and non-HPV-associated head and neck (H/N) cancer. J Clin Oncol. 2014;32:5s. Abstract 6011.

    Article  Google Scholar 

  124. Chow LQ, Burtness B, Weiss J, et al. A phase Ib study of pembrolizumab (Pembro; MK-3475) in patients (Pts) with human papilloma virus (HPV)-positive and negative head and neck cancer (HNC). Ann Oncol. 2014;25:v1–41. Abstract LBA31.

    Google Scholar 

  125. Vermorken JB, Psyrri A, Mesía R, et al. Impact of tumor HPV status on outcome in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck receiving chemotherapy with or without cetuximab: retrospective analysis of the phase III EXTREME trial. Ann Oncol. 2014;25:801–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  126. Vermorken J. Extreme (PF+/-cetuximab) and spectrum (PF+/- panitumumab): HPV status and outcome. Radiother Oncol. 2013;106(Suppl1):S2–3.

    Article  Google Scholar 

  127. Argiris A, Li S, Ghebremichael M, et al. Prognostic significance of human papillomavirus in recurrent or metastatic head and neck cancer: an analysis of Eastern Cooperative Oncology Group trials. Ann Oncol. 2014;25:1410–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  128. Argiris A, Buchanan A, Brockstein B, et al. Docetaxel and irinotecan in recurrent or metastatic head and neck cancer: a phase 2 trial of the Eastern Cooperative Oncology Group. Cancer. 2009;115:4504–13.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Internal Medicine, Hematology and Oncology, University Hospital Brno and Masaryk University, School of Medicine, Brno, Czech Republic

    Petr Szturz MD, PhD

  2. Department of Medical Oncology, Antwerp University Hospital, Wilrijkstraat 10, Edegem, 2650, Belgium

    Jan B. Vermorken MD, PhD

Authors
  1. Petr Szturz MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jan B. Vermorken MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jan B. Vermorken MD, PhD .

Editor information

Editors and Affiliations

  1. Department of Radio-Oncology, Genolier Swiss Medical Network, Genolier, Switzerland

    Jacques Bernier

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Szturz, P., Vermorken, J.B. (2016). Systemic Treatment of Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck. In: Bernier, J. (eds) Head and Neck Cancer. Springer, Cham. https://doi.org/10.1007/978-3-319-27601-4_42

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-27601-4_42

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-27599-4

  • Online ISBN: 978-3-319-27601-4

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation